Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60

Oppenheimer analyst Suraj Kalia has maintained an 'Outperform' rating on Pulse Biosciences (NASDAQ: PLSE) and increased the price target from $35 to $60. This adjustment reflects a positive outlook on the company's performance.